REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search
News

New Sheba Research Shows Encouraging Results for Schizophrenia Treatment

Schizophrenia Research Shows Promising Results
A recent study led by Prof. Mark Weiser, Director of the Psychiatric Division at Sheba Medical Center , confirmed a suspected link between using estrogen patches and the reduction in symptoms experienced by women with schizophrenia. Schizophrenia can be a debilitating disorder, and the results of this research offer a rare ray of hope to patients worldwide.

Researchers applied estrogen patches to premenopausal women with schizophrenia over an eight-week period. Following this period, the women experienced fewer hallucinations and delusions. They also demonstrated improved social skills and a new sense of initiative.

Many previous studies that investigated the treatment of schizophrenia resulted in inconsistent findings, with positive outcomes that could not be replicated. Consequently, schizophrenia is largely misunderstood. Yet, this new Israeli study was able to replicate and confirm the results discovered by Dr. Jayashri Kulkarni, Professor of Psychiatry at The Alfred and Monash University in Australia. The link between estrogen patches and an improvement in schizophrenia symptoms in women has now been scientifically verified.

“This is a significant breakthrough in the study of schizophrenia,” said Prof. Weiser. “These latest findings are a promising step toward understanding schizophrenia in women, and Sheba Medical Center is honored to be a part of this discovery.”

The promising results support the continued study of the relationship between estrogen and schizophrenia and highlight the pressing need to develop new chemical compounds that bind estrogen receptors in the brain. Additionally, they shed light on the ways in which men and women are affected differently.

The study was funded by the Stanley Medical Research Institute, a non-profit organization based in Washington, DC, and conducted in the Republic of Moldova.

Related
Sheba and Peter Mac
Sheba Joins Peter Mac for a New Prostate Cancer Treatment Trial
The POPSTAR II clinical trial, due to begin in early 2023 at multiple sites, will compare two cutting-edge treatments for men with advanced prostate cancer…
Read More
Blood Sensor
Sheba Begins Clinical Trial for INSPIRA Technologies’ Innovative HYLA Blood Sensor
Sheba Medical Center will begin a new clinical trial for the HYLA blood sensor developed by INSPIRA Technologies. The trial, led by Dr. Yigal Kassif,…
Read More
Sheba and AMH
Sheba Medical Center Will Bring Innovative Healthcare to Bahrain Through a New Partnership Agreement
Aiming to benefit patients in the Persian Gulf through the sharing of medical expertise, Sheba has concluded a partnership with Bahrain’s American Mission Hospital (AMH),…
Read More